Indication
Lipodystrophy associated with human immunodeficiency virus infection
Lipodystrophy associated with human immunodeficiency virus infection is an acquired disorder of adipose tissue distribution and metabolism occurring in individuals living with HIV, most frequently linked to antiretroviral therapy regimens. Read more about Lipodystrophy associated with human immunodeficiency virus infection
3 drugs 1 manufacturers
Drugs that treat it
Common Lipodystrophy associated with human immunodeficiency virus infection therapies.
EGRIFTA SV (tesamorelin acetate)
EGRIFTA WR (tesamorelin acetate)
News & literature
Coming soonRelated codes
Coming soonRelated conditions & guidelines
Coming soonLipodystrophy associated with human immunodeficiency virus infection is an acquired disorder of adipose tissue distribution and metabolism occurring in individuals living with HIV, most frequently linked to antiretroviral therapy regimens.
It primarily affects the adipose, metabolic, and cardiovascular systems and presents as lipoatrophy, lipohypertrophy, or a mixed phenotype.
Defining clinical features include the loss of peripheral subcutaneous adipose tissue in the face, limbs, and buttocks, abnormal visceral and truncal fat deposition in the abdomen, breasts, or dorsocervical region, and concurrent metabolic disruptions such as severe insulin resistance and dyslipidemia.
- nih.gov
Lipodystrophy associated with human immunodeficiency virus infection is an acquired disorder of adipose tissue distribution and metabolism occurring in individuals living with HIV, most frequently linked to antiretroviral therapy regimens Defining clinical features include the loss of peripheral subcutaneous adipose tissue in the face, limbs, and buttocks, abnormal visceral and truncal fat deposition in the abdomen, breasts, or dorsocervical region, and concurrent metabolic disruptions such as s...
- nih.gov
Lipodystrophy associated with human immunodeficiency virus infection is an acquired disorder of adipose tissue distribution and metabolism occurring in individuals living with HIV, most frequently linked to antiretroviral therapy regimens It primarily affects the adipose, metabolic, and cardiovascular systems and presents as lipoatrophy, lipohypertrophy, or a mixed phenotype Defining clinical features include the loss of peripheral subcutaneous adipose tissue in the face, limbs, and buttocks, ab...
Personalize your experience
Follow Lipodystrophy associated with human immunodeficiency virus infection and get updates as they land.
Already a member? Sign in
Follow an indication and get alerts when its drugs, labels, or guidelines change
Save any drug on this page to your favorites, synced across devices
AI-curated peer-reviewed research, summarized for your specialty
A morning digest of indication-relevant updates, when you want it
Sign in to follow this indication
Following an indication requires a free Physicians Office Resource account.